Please login to the form below

Not currently logged in
Email:
Password:

fast track appraisal

This page shows the latest fast track appraisal news and features for those working in and with pharma, biotech and healthcare.

NICE’s fast-track catapults Skyrizi into market

NICE’s fast-track catapults Skyrizi into market

The drug is one of the first treatments to go through NICE’s fast-track appraisal system, which accelerates the review process and also cuts the standard 90 day implementation period ... This is even faster than J&J’s rival IL-23 inhibitor Tremfya,

Latest news

  • AbbVie’s Skyrizi gets rapid ‘yes’ from NICE AbbVie’s Skyrizi gets rapid ‘yes’ from NICE

    New fast-track appraisal a boon for companies. AbbVie and Boehringer Ingelheim’s new psoriasis treatment Skyrizi has gained fast-track recommendation from NICE, coming less than three months after its ... AbbVie welcomed NICE’s decision, and said it

  • A first for Bluebird and Europe as gene therapy Zynteglo approved A first for Bluebird and Europe as gene therapy Zynteglo approved

    This was thanks to the EMA’s PRIME designation, a fast-track appraisal system particularly focused on cutting edge therapies from smaller-to-medium sized pharma and biotech firms.

  • NICE first fast-track appraisal backs Bayer's Eylea NICE first fast-track appraisal backs Bayer's Eylea

    The National Institute for Health and Care Excellence (NICE) has issued its first fast-track guidance, recommending Bayer’s Eylea (aflibercep) in choroidal neovascularisation (CNV). ... NICE’s fast track procedure is designed to give patients faster

  • NICE to create fast track for most cost-effective new drugs NICE to create fast track for most cost-effective new drugs

    Patients could get access to some medicines three months faster under a new 'fast track' appraisal process proposed by the UK's National Institute for Health and Care Excellence (NICE). ... Medicines qualifying for the fast-track process would have final

  • FDA will give BMS-Pfizer's Eliquis a priority review

    News that the FDA will fast-track its appraisal of the drug comes shortly after UK cost-effectiveness watchdog the National Institute for Health and Clinical Excellence (NICE) issued final draft ... This too was after a fast-tracked review process.

More from news
Approximately 1 fully matching, plus 11 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

Data desires
What are you looking to achieve with data and how are you preparing yourself to react to the results?...
The balancing act that’s keeping pharma and biotech market access on its toes
Pricing drugs and gaining reimbursement can be a real challenge for drug developers. Price it too high, and no one buys it. Price it too low, and it’s hard to...
Pills
Tackling antimicrobial resistance on multiple fronts
An urgent change of direction is needed in how we respond to AMR...

Infographics